• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在社区环境中,用于一线评估乳腺癌样本 HER2 状态的 FISH 与明场双探针原位杂交(BDISH)的可靠性评估:组织保存不良的影响。

Evaluation of reliability of FISH versus brightfield dual-probe in situ hybridization (BDISH) for frontline assessment of HER2 status in breast cancer samples in a community setting: influence of poor tissue preservation.

机构信息

Department of Anatomic Pathology, Hospital AC Camargo, São Paulo, SP, Brazil.

出版信息

Am J Surg Pathol. 2012 Oct;36(10):1489-96. doi: 10.1097/PAS.0b013e3182635987.

DOI:10.1097/PAS.0b013e3182635987
PMID:22982892
Abstract

AIMS

To evaluate the reliability of novel brightfield microscopy-based dual in situ hybridization (BDISH) methods for frontline HER2 status analysis in selected suboptimally preserved breast cancer tissue samples reflecting of the worst scenario in a community.

METHODS AND RESULTS

A total of 320 morphologically poorly preserved breast invasive ductal carcinomas from the archives of 2 tertiary institutions in Brazil were selected for a tissue microarray-based analysis. 4B5 antibody was used for immunohistochemistry. Fluorescence in situ hybridization (FISH), DuoCISH, ZytoDot CISH, and silver in situ hybridization (SISH) were performed and compared. The highest agreement was observed between SISH and FISH. In addition, SISH was easier to assess in both amplified and nonamplified cases when compared with the other chromogenic methods, due to the sharpness of its dots. DuoCISH produced false-positive results, associated with thicker ill-defined dots, causing poor distinction between nonamplification and low amplification. ZytoDot CISH showed lower sensitivity, with increased frequency of false-positive results.

CONCLUSIONS

SISH is the most reliable of the BDISH methods, with sensitivity and specificity highly comparable with FISH. It is also less deleterious than other BDISH methods, producing signals that were more distinct and therefore more readily analyzable even in poorly preserved tissue.

摘要

目的

评估新型亮场显微镜双重原位杂交(BDISH)方法在选择的、反映社区最差情况下的次优保存乳腺癌组织样本中进行一线 HER2 状态分析的可靠性。

方法和结果

从巴西 2 家 3 级医疗机构的档案中选择了 320 例形态学保存不佳的乳腺浸润性导管癌,进行基于组织微阵列的分析。使用 4B5 抗体进行免疫组织化学检测。进行了荧光原位杂交(FISH)、DuoCISH、ZytoDot CISH 和银原位杂交(SISH),并进行了比较。SISH 与 FISH 的一致性最高。此外,与其他显色方法相比,SISH 在扩增和非扩增病例中都更容易评估,因为其斑点更清晰。DuoCISH 产生了假阳性结果,与较厚的定义不明确的斑点相关,导致非扩增和低扩增之间难以区分。ZytoDot CISH 的敏感性较低,假阳性结果的频率增加。

结论

SISH 是 BDISH 方法中最可靠的方法,其敏感性和特异性与 FISH 高度可比。它也比其他 BDISH 方法的危害性更小,产生的信号更清晰,因此即使在保存不佳的组织中也更容易进行分析。

相似文献

1
Evaluation of reliability of FISH versus brightfield dual-probe in situ hybridization (BDISH) for frontline assessment of HER2 status in breast cancer samples in a community setting: influence of poor tissue preservation.在社区环境中,用于一线评估乳腺癌样本 HER2 状态的 FISH 与明场双探针原位杂交(BDISH)的可靠性评估:组织保存不良的影响。
Am J Surg Pathol. 2012 Oct;36(10):1489-96. doi: 10.1097/PAS.0b013e3182635987.
2
Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.使用组织微阵列对乳腺癌HER2基因扩增进行明场原位杂交:显色法(CISH)和自动银增强法(SISH)与患者预后的相关性
Diagn Mol Pathol. 2009 Jun;18(2):88-95. doi: 10.1097/PDM.0b013e31816f6374.
3
Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens.评估自动银增强原位杂交(SISH)用于检测乳腺癌切除标本和粗针活检标本中HER2基因扩增的情况。
Histopathology. 2009 Jan;54(2):248-53. doi: 10.1111/j.1365-2559.2008.03185.x.
4
[HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].[通过双色原位杂交(dc-CISH)评估浸润性乳腺癌中HER-2癌基因扩增:与荧光原位杂交(FISH)的比较研究]
Ann Pathol. 2011 Dec;31(6):472-9. doi: 10.1016/j.annpat.2011.10.013. Epub 2011 Nov 26.
5
Effectiveness of silver-enhanced in situ hybridization for evaluating HER2 gene status in invasive breast carcinoma: a comparative study.银增强原位杂交在评估浸润性乳腺癌 HER2 基因状态中的有效性:一项对比研究。
Arch Med Res. 2012 Feb;43(2):139-44. doi: 10.1016/j.arcmed.2012.03.010. Epub 2012 Apr 1.
6
Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing.双色显色原位杂交在 HER2 检测中可能是荧光原位杂交的替代方法。
Histopathology. 2011 Nov;59(5):984-92. doi: 10.1111/j.1365-2559.2011.04037.x.
7
Determination of the Her-2/neu gene amplification status in cytologic breast cancer specimens using automated silver-enhanced in-situ hybridization (SISH).应用自动化银增强原位杂交(SISH)技术检测细胞学乳腺癌标本中 Her-2/neu 基因扩增状态。
Am J Surg Pathol. 2010 Aug;34(8):1180-5. doi: 10.1097/PAS.0b013e3181e70e15.
8
Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?用于检测乳腺癌中HER-2/neu基因扩增的显色原位杂交,重点关注临界和低水平扩增的肿瘤:它能与荧光原位杂交相媲美吗?
Am J Clin Pathol. 2005 Feb;123(2):237-43.
9
Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).采用双色显色原位杂交(dual CISH)检测浸润性乳腺癌 HER2 基因扩增。
Pathol Int. 2010 Jul;60(7):510-5. doi: 10.1111/j.1440-1827.2010.02553.x.
10
The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer.双色显色原位杂交与荧光原位杂交在评估乳腺癌HER2基因扩增中的相关性
Diagn Mol Pathol. 2009 Jun;18(2):96-102. doi: 10.1097/PDM.0b013e31817f5227.

引用本文的文献

1
High HER2 Intratumoral Heterogeneity Is a Predictive Factor for Poor Prognosis in Early-Stage and Locally Advanced HER2-Positive Breast Cancer.高HER2肿瘤内异质性是早期和局部晚期HER2阳性乳腺癌预后不良的预测因素。
Cancers (Basel). 2024 Mar 5;16(5):1062. doi: 10.3390/cancers16051062.
2
Problems In Determining Her2 Status In Breast Carcinoma.确定乳腺癌中Her2状态的问题
J Breast Health. 2015 Jan 1;11(1):10-16. doi: 10.5152/tjbh.2014.2103. eCollection 2015 Jan.
3
HER2 status determination: analyzing the problems to find the solutions.
人表皮生长因子受体2(HER2)状态的判定:分析问题以寻找解决方案
Medicine (Baltimore). 2015 Apr;94(15):e645. doi: 10.1097/MD.0000000000000645.
4
Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplification.通过免疫组织化学(IHC)和银增强原位杂交(SISH)同时检测HER2蛋白和基因改变,可识别有无基因扩增的HER2阳性乳腺癌。
PLoS One. 2014 Aug 25;9(8):e105961. doi: 10.1371/journal.pone.0105961. eCollection 2014.